Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs

Cell Death and Differentiation

Volumn 22, Issue 12, 2015, Pages 1946-1956

  Hugle, M ^a   Belz, K ^a   Fulda, S ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CASPASE; NAVELBINE; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VOLASERTIB; CELL CYCLE PROTEIN; MCL1 PROTEIN, HUMAN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN BAK; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; TUBULIN MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; LETHALITY; MITOSIS; MITOSIS INHIBITION; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; MICE; MITOCHONDRIA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PTERIDINES; REACTIVE OXYGEN SPECIES; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 84947040545     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.59     Document Type: Article

References (33)

1. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
2. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-464.
3. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
4. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007; 26: 7773-7779.
5. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-660.
6. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009; 8: 3024-3035.
7. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26: 2093-2108.
8. Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME et al. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar rhabdomyosarcoma. Cancer Res 2015; 75: 98-110.
9. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-3102.
10. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008; 68: 7956-7965.
11. Naumann I, Kappler R, von Schweinitz D, Debatin KM, Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res 2011; 17: 3204-3218.
12. Hans F, Dimitrov S. Histone H3 phosphorylation and cell division. Oncogene 2001; 20: 3021-3027.
13. Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 2010; 29: 2407-2420.
14. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109.
15. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114.
16. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
17. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17: 1475-1486.
18. van Loo G, Schotte P, van Gurp M, Demol H, Hoorelbeke B, Gevaert K et al. Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ 2001; 8: 1136-1142.
19. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-99.
20. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67: 2908-2911.
21. Eichhorn JM, Sakurikar N, Alford SE, Chu R, Chambers TC. Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis 2013; 4: e834.
22. Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010; 30: 640-656.
23. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S et al. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008; 283: 35517-35525.
24. Sarsour EH, Kalen AL, Goswami PC. Manganese superoxide dismutase regulates a redox cycle within the cell cycle. Antioxidants Redox Signal 2014; 20: 1618-1627.
25. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012 19: 107-120.
26. Gjertsen BT, Schoffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015; 29: 11-19.
27. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH et al. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2014; 61: 158-164.
28. Sandler E, Lyden E, Ruymann F, Maurer H, Wharam M, Parham D et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001; 37: 442-448.
29. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012; 59: 5-10.
30. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
31. Rapino F, Naumann I, Fulda S. Bortezomib antagonizes microtubule-interfering druginduced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death Dis 2013; 4: e925.
32. Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J Biol Chem 2013; 288: 35287-35296.
33. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed), Synergism and Antagonism in Chemotherapy. Academic Press: San Diego, USA, 1991 pp 61-102.